Q1 2025 HLS Therapeutics Inc Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: C$4.6 (+2.45%)

Transcript

Key Points

Positve

HLS Therapeutics Inc (HLTRF) has secured new cardiovascular products, Nexool and Nexlozab, which align with their business development strategy and have significant commercial potential.
The company achieved a 34% growth in net sales and a 29% increase in CP units in Q1, indicating strong demand and effective sales strategies.
HLS Therapeutics Inc (HLTRF) has successfully restructured its sales leadership, leading to improved commercial performance and regional growth opportunities.
The company reported a 41% increase in adjusted EBITDA compared to the previous year, demonstrating improved financial performance.
HLS Therapeutics Inc (HLTRF) has made progress in reducing operating expenses by 20%, showcasing operational efficiency improvements.

Negative

Foreign exchange changes negatively impacted Q1 revenue by approximately $0.6 million.
Royalty revenue decreased significantly from $0.7 million in Q1 last year to $0.2 million in Q1 2025 due to the sale of royalty interests.
There is uncertainty regarding the reimbursement process and pricing for the new cardiovascular products, which could impact future revenue.
The company anticipates a two-year timeline to achieve broad public reimbursement for the new products, potentially delaying revenue realization.
Despite improvements, there are still challenges in converting existing patients to the enhanced co-pay assistance program for Visepa.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HLS.TO - HLS Therapeutics Inc
Q1 2025 HLS Therapeutics Inc Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
So excited about Net Flatto and next Lisette.

These medicines perfectly align with the business development approach and portfolio expansion criteria that I've discussed previously.

These are highly differentiated commercial stage assets that come with compelling clinical data.

They're already generating significant revenue in the US and Europe and will have considerable commercial potential when approved in Canada.

Importantly, we secured these assets without requiring significant upfront capital, and we don't expect substantial additional OpEx investment is necessary for commercialization.

Being complementary to the SEPA will leverage our existing infrastructure and capabilities to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.